Physician profile
Joseph Sadowski
NPI 1790737849
$4,197.69
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $595 · 2021: $628 · 2022: $702 · 2023: $854 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.40 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $637.32 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $569.65 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $340.88 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $289.79 | 2019-2022 | |
| Amarin Pharma, INC. | $217.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.29 | 2019-2020 | |
| Pfizer INC. | $170.37 | 2019-2023 | |
| Astellas Pharma US INC | $143.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $140.31 | 2019-2021 | |
| Allergan, INC. | $117.13 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.69 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $97.14 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $84.04 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $75.24 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $64.06 | 2022 | |
| Esperion Therapeutics, INC. | $59.14 | 2023-2024 | Nexletol |
| Lilly USA, LLC | $57.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.70 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $43.15 | 2019 | |
| Exact Sciences Corporation | $26.07 | 2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $22.55 | 2023 | Krystexxa |
| Eisai INC. | $18.52 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.95 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sadowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.